Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations (Unaudited)

v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Statement [Abstract]        
Research and development (“R&D”) expenses, net $ 5,014 $ 6,897 $ 10,264 $ 11,002
General and administrative expenses 2,419 2,828 4,925 5,508
Operating loss 7,433 9,725 15,189 16,510
Other expenses (income) 70 (2,017) 76 (2,105)
Interest expenses 5 13 10 863
Income from change in fair value of warrants (1,498) (11,868) (2,412) (3,858)
Finance expense (income), net 25 (329) 830 1,436
Loss (income) before tax 6,035 (4,476) 13,693 12,846
Tax expenses 2 5 3 10
Net loss (income) $ 6,037 $ (4,471) $ 13,696 $ 12,856
Basic loss (earnings) per share of Common Stock (in Dollars per share) $ 0.19 $ (0.14) $ 0.5 $ 1.95
Diluted loss per share of Common Stock (in Dollars per share) $ 0.19 $ 0.69 $ 0.5 $ 1.95
Weighted average number of shares used in computing basic loss (earnings) per share of Common Stock (in Shares) 31,308,396 6,980,943 27,250,021 6,605,952
Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares) 31,308,396 10,750,194 27,250,021 6,605,952